SLSSellas Life Sciences GroupSigning up patients
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Hematologic Malignancies
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 160 (planned)
- Started
- May 10, 2021
- Main results expected
- Dec 30, 2026
- Fully finished
- Dec 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Safety and Tolerability: Dose Limiting Toxicities (DLTs)
Measured over: 21 to 28 days
Safety and Tolerability: adverse events (AEs)
Measured over: approximately 2 years
Efficacy: ORR
Measured over: 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04588922 · record last updated 2026-09-03 · checked 2026-11-09 15:36 UTC